This trial is active, not recruiting.

Condition hepatocellular carcinoma
Treatments sir-spheres, sorafenib tosylate
Phase phase 3
Sponsor Singapore General Hospital
Collaborator National Cancer Centre, Singapore
Start date July 2010
End date April 2017
Trial size 360 participants
Trial identifier NCT01135056, AHCC06


The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).

The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Sorafenib tosylate: Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma.
sorafenib tosylate Nexavar
Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
(Active Comparator)
SIR-Spheres: SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value. SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver.
sir-spheres Yttrium-90 Microspheres
One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.

Primary Outcomes

Overall Survival
time frame: 2 years

Secondary Outcomes

Progression free survival in the liver
time frame: 2 years
Progression free survival overall
time frame: 2 years
Tumour Response Rate
time frame: 2 years
Toxicity and Safety
time frame: Up to 2 years
Health Related Quality of Life (QoL)
time frame: Up to 2 years
Liver resection rate
time frame: Up to 2 years
Liver Transplantation Rate
time frame: Up to 2 years
Time to Disease Progression
time frame: Up to 2 years
Disease control rate
time frame: 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Disease must be locally advanced as defined by BCLC (B) intermediate stage or BCLC (C) advanced stage without extra-hepatic disease (only with branch portal vein thrombosis). - Willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the subject's routine care. - Aged 18 years/older (either gender). - Unequivocal diagnosis of HCC. - HCC not amenable to surgical resection or immediate liver transplantation, or cannot be optimally treated with local ablative techniques such as RFA, consistent with the practice of the clinical trial centre. - Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with spiral CT scan or MRI. - ECOG performance status 0-1. - Child-Pugh A-B (up to 7 points) - Adequate haematological, renal and hepatic function as follows: - Leukocytes ≥ 2,500/μL - Platelets ≥ 80,000/μL - Haemoglobin > 9.5g/dL - Total bilirubin < 2.0mg/dL - INR ≤ 2.0 - ALP ≤ 5 x institutional ULN - AST and ALT ≤ 5 x institutional ULN - Albumin ≥ 2.5g/dL - Creatinine ≤ 2.0mg/dL - Life expectancy of at least 3 months without any active treatment. - Suitable for protocol treatment as determined by clinical assessment undertaken by the Investigator. - Female patients must be either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use 2 forms of contraception if sexually active during their study participation. - Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner then must be using an acceptable form of contraception. Exclusion Criteria: - Have had more than 2 administrations of hepatic artery directed therapy. - Subjects who have had hepatic artery directed therapy done < 4 weeks prior to study entry. - Have had systemic chemotherapy for HCC except for prior adjuvant or neoadjuvant therapy given more than 6 months from enrolment. - have had prior treatment with Sorafenib or VEGF inhibitors. - Prior hepatic radiation therapy for HCC or other malignancy. - Currently receiving any other investigational agents for the treatment of their cancer. - Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination. - Complete main portal vein thrombosis. - Any metastatic disease (local-regional lymph nodes measuring less than 2 cm in greatest diameter or lung nodules measuring less than 1 cm are not contraindications as per Investigator discretion). - Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years. - Presence of clinical signs of CNS metastases due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events. - Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Any of the following contraindications to angiography and selective visceral catheterization: - Bleeding diathesis, not correctable by the standard forms of therapy. - Severe peripheral vascular disease that would preclude arterial catheterization. - Portal hypertension with hepato-fugal flow as documented on baseline spiral CT scan. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIR-Spheres or Sorafenib. - Inability or unwillingness to understand or sign a written informed consent document. - Female subjects who are pregnant or currently breastfeeding. - Female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as per Investigator discretion during the study. The rhythm method is not to be used as the sole method of contraception. - Male subjects, unwillingness to practice effective contraception (per Investigator discretion) while taking part in this study, because the effect of the SIR-Spheres treatment on sperm or upon the development of an unborn child are unknown. - Current enrolment in any other investigational therapeutic drug or device study.

Additional Information

Official title Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Description Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide but unfortunately between 70 - 80% of all HCC are in the Asia-Pacific because of the prevalence of chronic viral hepatitis in the region. The increase in the prevalence of chronic hepatitis C in the Western world however predicts that HCC will similarly be an important cause of death there in the next 20 years. Only 15-20% of HCC are today potentially curable by surgery at the time of diagnosis. Another 10-15% of patients may benefit from potentially curative locally ablative therapy such as radio-frequency ablation. Prognosis in the majority of patients has been dismal as conventional systemic therapies have been largely inefficacious. The first successfully trialed systemic targeted therapy, sorafenib (2007) prolonged survival by a modest average of 3 months in patients with good underlying liver function. While the liver is radio-sensitive, external beam radiation causes significant radio-toxicity. To overcome this, selective internal radiation therapy (SIRT) was developed to deliver a radiation source directly to liver cancer via the arterial route. Sir-sphere is radioactive yttrium on a 90 micro-meter diameter resin carrier and is an established therapy in colorectal metastasis. Sir-sphere has been reported to cause significantly tumour regression in HCC. This study will evaluate the efficacy of SIRT using SIR-Spheres yttrium-90 microspheres compared to sorafenib in the treatment of patients with locally advanced primary HCC.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Singapore General Hospital.